China is a high-incidence country of gastric cancer(GC),most patients have been diagnosed when the development of local progression or advanced stage,and advanced GC as our country's treatment field can not avoid a major problem,there is always a lack of effective treatment.With the advent of programmed death receptor 1(PD-1)or programmed death receptor ligand 1(PD-L1)monoclonal antibody,that it can effectively improve the overall survival rate of patients with advanced GC have been found.Therefore,there is a great upsurge of immunologic research for GC worldwide.This article reviews the progress of PD-1 inhibitors in the mechanism of action,clinical immunotherapeutic efficacy,adverse reactions and so on.
gastric cancerimmunotherapyprogrammed death receptor 1(PD-1)inhibitor
NETL
NSTL
万方数据
